American Society of Hirudotherapy

Platelet aggregation inhibitors from hematophagous animals

Research article published in Toxicon : official journal of the International Society on Toxinology (2010)

Last Updated: March 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Salivary PharmacologyGenomics & ProteomicsFrancischetti I · Toxicon : official journal of the International Society on Toxinology, 2010

Abstract

Salivary glands from blood-sucking animals (e.g., mosquitoes, bugs, sand flies, fleas, ticks, leeches, hookworms, bats) are a rich source of bioactive molecules that counteract hemostasis in a redundant and synergistic manner. This review discusses recent progress in the identification of salivary inhibitors of platelet aggregation, their molecular characterization, and detailed mechanism of action. Diversity of inhibitors is remarkable, with distinct families of proteins characterized as apyrases that enzymatically degrade ADP or as collagen-binding proteins that prevent its interaction with vWF, or platelet integrin α2β1 or GPVI. Molecules that bind ADP, TXA(2), epinephrine, or serotonin with high affinity have also been cloned, expressed, and their structure determined. In addition, a repertoire of antithrombins and an increasingly number of RGD and non-RGD disintegrins targeting platelet αIIbβ3 have been reported. Moreover, metalloproteases with fibrinogen(olytic) activity and PAF phosphorylcholine hydrolase are enzymes that have been recruited to the salivary gland to block platelet aggregation. Platelet inhibitory prostaglandins, lysophosphatydilcholine, adenosine, and nitric oxide (NO)-carrying proteins are other notable examples of molecules from hematophagous salivary secretions (herein named sialogenins) with antihemostatic properties. Sialogenins have been employed as tools in biochemistry and cell biology and also display potential therapeutic applications.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, N.I.H., IntramuralReview
Indexed MeSH termsAnimalsApyraseArthropodsFeeding BehaviorInsect ProteinsModels, BiologicalMolecular Sequence DataPlatelet Aggregation InhibitorsProtein Structure, TertiarySalivary GlandsSequence Alignment

Summary

Salivary glands from blood-sucking animals (e. g.

Why This Matters for Hirudotherapy

Advances understanding of leech salivary bioactive compounds and their therapeutic potential.

Citation

Platelet aggregation inhibitors from hematophagous animals.

Francischetti I · Toxicon : official journal of the International Society on Toxinology, 2010

Added to ASH library: March 18, 2026 · Site last updated: March 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.

Platelet aggregation inhibitors from hematophagous animals | ASH